These suggested that 18F-APN-1607 PET may serve as an effective imaging marker for visualizing the change of tau protein deposition in AD patients, and its uptake pattern in different brain regions may relate to the progress of cognitive impairment. This evidence concerns the gene MAPT and Cognitive impairment.